Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents

Advanced Drug Delivery Reviews

Volumn 64, Issue 7, 2012, Pages 605-613

  Biddlestone Thorpe, Laura ^a   Marchi, Nicola ^b   Guo, Kathy ^b   Ghosh, Chaitali ^b   Janigro, Damir ^b   Valerie, Kristoffer ^a   Yang, Hu ^a,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Virginia Commonwealth University   (United States)

Author keywords

Blood brain barrier (BBB); Brain cancer; Central nervous system (CNS); Convection enhanced delivery (CED); Flow based in vitro BBB model; Nanoparticle

Indexed keywords

BLOOD-BRAIN BARRIER; BRAIN CANCER; CENTRAL NERVOUS SYSTEMS; CONVECTION-ENHANCED DELIVERY; IN-VITRO;

BLOOD; DIFFUSION BARRIERS; DISEASES; NANOPARTICLES; NANOSTRUCTURED MATERIALS; POLYMERS; TRANSPORTATION ROUTES;

DIAGNOSIS;

ANTHRACYCLINE DERIVATIVE; AZD 2262; CAMPTOTHECIN; CARMUSTINE; DOXORUBICIN; GLUCOSE TRANSPORTER 1; INIPARIB; KU 60019; LIPOSOME; LOPERAMIDE; MANNITOL; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; NANOMATERIAL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; POLOXAMER; POLYGLACTIN; TAXANE DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCA ALKALOID;

ACTIVE TRANSPORT; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER RESISTANCE; CENTRAL NERVOUS SYSTEM; CONTROLLED DRUG RELEASE; CONVECTION ENHANCED DELIVERY; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; ENCAPSULATION; ENDOCYTOSIS; EPILEPSY; GLIOBLASTOMA; GLIOMA; HUMAN; MICROVASCULAR ENDOTHELIAL CELL; NANOPHARMACEUTICS; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION; UNSPECIFIED SIDE EFFECT;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS;

EID: 84859979641     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.11.014     Document Type: Review

References (81)

1. Lesniak M.S., Brem H. Targeted therapy for brain tumours. Nat. Rev. Drug Discov. 2004, 3:499-508.
2. Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm. Res. 2010, 27:1759-1771.
3. Grant G.A., Janigro D. The blood-brain barrier. Youmans Neurological Surgery 2004, 153-174. Saunders, Philadelphia, PA. H.R. Winn (Ed.).
4. Neuwelt E.A., Bauer B., Fahlke C., Fricker G., Iadecola C., Janigro D., Leybaert L., Molnar Z., O'Donnell M.E., Povlishock J.T., Saunders N.R., Sharp F., Stanimirovic D., Watts R.J., Drewes L.R. Engaging neuroscience to advance translational research in brain barrier biology. Nat. Rev. Neurosci. 2011, 12:169-182.
5. Maher F., Vannucci S.J., Simpson I.A. Glucose transporter proteins in brain. FASEB J. 1994, 8:1003-1011.
6. Loscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 2005, 6:591-602.
7. Marchi N., Gonzalez-Martinez J., Nguyen M.T., Granata T., Janigro D. Transporters in drug-refractory epilepsy: clinical significance. Clin. Pharmacol. Ther. 2010, 87:13-15.
8. Reinhardt R.R., Bondy C.A. Insulin-like growth factors cross the blood-brain barrier. Endocrinology 1994, 135:1753-1761.
9. Golden P.L., Maccagnan T.J., Pardridge W.M. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J. Clin. Invest 1997, 99:14-18.
10. Fishman J.B., Rubin J.B., Handrahan J.V., Connor J.R., Fine R.E. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 1987, 18:299-304.
11. Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 2007, 170:1445-1453.
12. Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A., Hahn W.C., Ligon K.L., Louis D.N., Brennan C., Chin L., DePinho R.A., Cavenee W.K. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007, 21:2683-2710.
13. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
14. Schouten L.J., Rutten J., Huveneers H.A., Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002, 94:2698-2705.
15. Buonerba C., Di Lorenzo G., Marinelli A., Federico P., Palmieri G., Imbimbo M., Conti P., Peluso G., De Placido S., Sampson J.H. A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit. Rev. Oncol. Hematol. 2010.
16. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
17. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., Alexe G., Lawrence M., O'Kelly M., Tamayo P., Weir B.A., Gabriel S., Winckler W., Gupta S., Jakkula L., Feiler H.S., Hodgson J.G., James C.D., Sarkaria J.N., Brennan C., Kahn A., Spellman P.T., Wilson R.K., Speed T.P., Gray J.W., Meyerson M., Getz G., Perou C.M., Hayes D.N. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
18. Bidros D.S., Liu J.K., Vogelbaum M.A. Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol. 2010, 6:117-125.
19. Kreuter J. Drug targeting with nanoparticles. Eur. J. Drug Metab. Pharmacokinet. 1994, 19:253-256.
20. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 2001, 47:65-81.
21. Rapoport S.I. Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy. Expert Opin. Investig. Drugs 2001, 10:1809-1818.
22. Zylber-Katz E., Gomori J.M., Schwartz A., Lossos A., Bokstein F., Siegal T. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Clin. Pharmacol. Ther. 2000, 67:631-641.
23. Rempe R., Cramer S., Huwel S., Galla H.J. Transport of poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. Biochem. Biophys. Res. Commun. 2011, 406:64-69.
24. Wohlfart S., Khalansky A.S., Gelperina S., Maksimenko O., Bernreuther C., Glatzel M., Kreuter J. Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS One 2011, 6:e19121.
25. Michaelis K., Hoffmann M.M., Dreis S., Herbert E., Alyautdin R.N., Michaelis M., Kreuter J., Langer K. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther. 2006, 317:1246-1253.
26. Steiniger S.C., Kreuter J., Khalansky A.S., Skidan I.N., Bobruskin A.I., Smirnova Z.S., Severin S.E., Uhl R., Kock M., Geiger K.D., Gelperina S.E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 2004, 109:759-767.
27. Ashby L.S., Ryken T.C. Management of malignant glioma: steady progress with multimodal approaches. Neurosurg. Focus 2006, 20:E3.
28. Freilich R.J., Seidman A.D., DeAngelis L.M. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 1995, 76:232-236.
29. Forsyth P., Cairncross G., Stewart D., Goodyear M., Wainman N., Eisenhauer E. Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. Invest. New Drugs 1996, 14:203-206.
30. Mardor Y., Roth Y., Lidar Z., Jonas T., Pfeffer R., Maier S.E., Faibel M., Nass D., Hadani M., Orenstein A., Cohen J.S., Ram Z. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. 2001, 61:4971-4973.
31. Walter K.A., Cahan M.A., Gur A., Tyler B., Hilton J., Colvin O.M., Burger P.C., Domb A., Brem H. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res. 1994, 54:2207-2212.
32. Li K.W., Dang W., Tyler B.M., Troiano G., Tihan T., Brem H., Walter K.A. Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies. Clin. Cancer Res. 2003, 9:3441-3447.
33. Kawano K., Watanabe M., Yamamoto T., Yokoyama M., Opanasopit P., Okano T., Maitani Y. Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J. Control Release 2006, 112:329-332.
34. Storm P.B., Moriarity J.L., Tyler B., Burger P.C., Brem H., Weingart J. Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy. J. Neurooncol 2002, 56:209-217.
35. Weingart J.D., Thompson R.C., Tyler B., Colvin O.M., Brem H. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int. J. Cancer 1995, 62:605-609.
36. Sawyer A.J., Piepmeier J.M., Saltzman W.M. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J. Biol. Med. 2006, 79:141-152.
37. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:2076-2080.
38. Chen M.Y., Lonser R.R., Morrison P.F., Governale L.S., Oldfield E.H. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J. Neurosurg. 1999, 90:315-320.
39. Morrison P.F., Chen M.Y., Chadwick R.S., Lonser R.R., Oldfield E.H. Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. Am. J. Physiol. 1999, 277:R1218-R1229.
40. Krauze M.T., Saito R., Noble C., Tamas M., Bringas J., Park J.W., Berger M.S., Bankiewicz K. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J. Neurosurg. 2005, 103:923-929.
41. Raghavan R., Brady M.L., Rodriguez-Ponce M.I., Hartlep A., Pedain C., Sampson J.H. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg. Focus 2006, 20:E12.
42. Oh S., Odland R., Wilson S.R., Kroeger K.M., Liu C., Lowenstein P.R., Castro M.G., Hall W.A., Ohlfest J.R. Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J. Neurosurg. 2007, 107:568-577.
43. Hadjipanayis C.G., Machaidze R., Kaluzova M., Wang L., Schuette A.J., Chen H., Wu X., Mao H. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 2010, 70:6303-6312.
44. Krauze M.T., Noble C.O., Kawaguchi T., Drummond D., Kirpotin D.B., Yamashita Y., Kullberg E., Forsayeth J., Park J.W., Bankiewicz K.S. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol. 2007, 9:393-403.
45. Krauze M.T., Vandenberg S.R., Yamashita Y., Saito R., Forsayeth J., Noble C., Park J., Bankiewicz K.S. Safety of real-time convection-enhanced delivery of liposomes to primate brain: a long-term retrospective. Exp. Neurol. 2008, 210:638-644.
46. Sawyer A., Saucier-Sawyer J., Booth C., Liu J., Patel T., Piepmeier J., Saltzman W. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv. Transl. Res. 2011, 1:34-42.
47. Rao K.S., Reddy M.K., Horning J.L., Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 2008, 29:4429-4438.
48. Gupta B., Levchenko T.S., Torchilin V.P. TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol. Res. 2007, 16:351-359.
49. Lerner E.N., van Zanten E.H., Stewart G.R. Enhanced delivery of octreotide to the brain via transnasal iontophoretic administration. J. Drug Target. 2004, 12:273-280.
50. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 2010, 99:1654-1673.
51. Illum L., Watts P., Fisher A.N., Hinchcliffe M., Norbury H., Jabbal-Gill I., Nankervis R., Davis S.S. Intranasal delivery of morphine. J. Pharmacol. Exp. Ther. 2002, 301:391-400.
52. Wong Y.C., Zuo Z. Intranasal delivery - modification of drug metabolism and brain disposition. Pharm. Res. 2010, 27:1208-1223.
53. Arumugam K., Subramanian G.S., Mallayasamy S.R., Averineni R.K., Reddy M.S., Udupa N. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm. 2008, 58:287-297.
54. Liu Q., Shao X., Chen J., Shen Y., Feng C., Gao X., Zhao Y., Li J., Zhang Q., Jiang X. In vivo toxicity and immunogenicity of wheat germ agglutinin conjugated poly(ethylene glycol)-poly(lactic acid) nanoparticles for intranasal delivery to the brain. Toxicol. Appl. Pharmacol. 2011, 251:79-84.
55. Shingaki T., Inoue D., Furubayashi T., Sakane T., Katsumi H., Yamamoto A., Yamashita S. Transnasal delivery of methotrexate to brain tumors in rats: a new strategy for brain tumor chemotherapy. Mol. Pharm. 2010, 7:1561-1568.
56. Mangal S., Pawar D., Garg N.K., Jain A.K., Vyas S.P., Rao D.S., Jaganathan K.S. Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally. Vaccine 2011, 29:4953-4962.
57. Gao X., Chen J., Chen J., Wu B., Chen H., Jiang X. Quantum dots bearing lectin-functionalized nanoparticles as a platform for in vivo brain imaging. Bioconjug. Chem. 2008, 19:2189-2195.
58. Kumar M., Misra A., Babbar A.K., Mishra A.K., Mishra P., Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm. 2008, 358:285-291.
59. Desai S.Y., Marroni M., Cucullo L., Krizanac-Bengez L., Mayberg M.R., Hossain M.T., Grant G.G., Janigro D. Mechanisms of endothelial survival under shear stress. Endothelium 2002, 9:89-102.
60. Cucullo L., Hossain M., Puvenna V., Marchi N., Janigro D. The role of shear stress in Blood-brain Barrier endothelial physiology. BMC Neurosci. 2011, 12:40.
61. Oby E., Janigro D. The blood-brain barrier and epilepsy. Epilepsia 2006, 47:1761-1774.
62. Marchi N., Angelov L., Masaryk T., Fazio V., Granata T., Hernandez N., Hallene K., Diglaw T., Franic L., Najm I., Janigro D. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 2007, 48:732-742.
63. Marchi N., Granata T., Freri E., Ciusani E., Ragona F., Puvenna V., Teng Q., Alexopolous A., Janigro D. Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS One 2011, 6:e18200.
64. Cucullo L., Hossain M., Rapp E., Manders T., Marchi N., Janigro D. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 2007, 48:505-516.
65. Cucullo L., Couraud P.O., Weksler B., Romero I.A., Hossain M., Rapp E., Janigro D. Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies. J. Cereb. Blood Flow Metab. 2008, 28:312-328.
66. Cucullo L., Marchi N., Hossain M., Janigro D. A dynamic in vitro BBB model for the study of immune cell trafficking into the central nervous system. J. Cereb. Blood Flow Metab. 2011, 31:767-777.
67. Stanness K.A., Westrum L.E., Fornaciari E., Mascagni P., Nelson J.A., Stenglein S.G., Myers T., Janigro D. Morphological and functional characterization of an in vitro blood-brain barrier model. Brain Res. 1997, 771:329-342.
68. Stanness K.A., Neumaier J.F., Sexton T.J., Grant G.A., Emmi A., Maris D.O., Janigro D. A new model of the blood-brain barrier: co-culture of neuronal, endothelial and glial cells under dynamic conditions. Neuroreport 1999, 10:3725-3731.
69. Marchi N., Hallene K.L., Kight K.M., Cucullo L., Moddel G., Bingaman W., Dini G., Vezzani A., Janigro D. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med. 2004, 2:37.
70. Dombrowski S.M., Desai S.Y., Marroni M., Cucullo L., Goodrich K., Bingaman W., Mayberg M.R., Bengez L., Janigro D. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001, 42:1501-1506.
71. Santaguida S., Janigro D., Hossain M., Oby E., Rapp E., Cucullo L. Side by side comparison between dynamic versus static models of blood-brain barrier in vitro: a permeability study. Brain Res. 2006, 1109:1-13.
72. Ghosh C., Gonzalez-Martinez J., Hossain M., Cucullo L., Fazio V., Janigro D., Marchi N. Pattern of P450 expression at the human blood-brain barrier: roles of epileptic condition and laminar flow. Epilepsia 2010, 51:1408-1417.
73. Ghosh C., Puvenna V., Gonzalez-Martinez J., Janigro D., Marchi N. Blood-brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases. Curr Drug Metab 2011, 12:742-749.
74. Ghosh C., Marchi N., Desai N.K., Puvenna V., Hossain M., Gonzalez-Martinez J., Alexopoulos A.V., Janigro D. Cellular localization and functional significance of CYP3A4 in the human epileptic brain. Epilepsia 2011, 52:562-571.
75. Evers B., Helleday T., Jonkers J. Targeting homologous recombination repair defects in cancer. Trends Pharmacol. Sci. 2010, 31:372-380.
76. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8:193-204.
77. Bolderson E., Richard D.J., Zhou B.B., Khanna K.K. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin. Cancer Res. 2009, 15:6314-6320.
78. accessed June 3rd, 2011. http://www.clinicaltrials.gov/ct2/show/NCT00687765?term=bsi-201&rank=2.
79. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
80. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
81. Golding S.E., Rosenberg E., Valerie N., Hussaini I., Frigerio M., Cockcroft X.F., Chong W.Y., Hummersone M., Rigoreau L., Menear K.A., O'Connor M.J., Povirk L.F., van Meter T., Valerie K. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 2009, 8:2894-2902.